Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)-Reference-Cited by-同舟云学术

Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)

Published:2021-07 Issue: Volume:152 Page:116-128
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Gogas Helen,Dummer Reinhard,Ascierto Paolo A.^ORCID,Arance Ana,Mandalà Mario,Liszkay Gabriella,Garbe Claus^ORCID,Schadendorf Dirk,Krajsová Ivana,Gutzmer Ralf^ORCID,Sileni Vanna Chiarion,Dutriaux Caroline,Yamazaki Naoya,Loquai Carmen,Queirolo Paola,Jan de Willem Groot,Sellier Abir Tadmouri,Suissa Jeanne,Murris Juliette^ORCID,Gollerkeri Ashwin^ORCID,Robert Caroline,Flaherty Keith T.^ORCID

Funder

Pfizer Inc Boulder

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference31 articles.

1. The Global Cancer Observatory,2020

2. The role of BRAF V600 mutation in melanoma;Ascierto;J Transl Med,2012

3. Beyond BRAF: where next for melanoma therapy?;Fedorenko;Br J Canc,2015

4. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations;Trojaniello;Expet Rev Clin Pharmacol,2019

5. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial;Dummer;Lancet Oncol,2018

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding quality of life issues in patients with advanced melanoma: Phase 1 and 2 in the development of the EORTC advanced melanoma module;European Journal of Cancer;2024-08

2. Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial;Journal of Clinical Oncology;2023-10-10

3. Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review;European Journal of Cancer;2023-05

4. The benefit of early‐stage diagnosis: A registry‐based survey evaluating the quality of life in patients with melanoma;Skin Health and Disease;2023-04-17

5. Theranostic Activity of Ceria-Based Nanoparticles toward Parental and Metastatic Melanoma: 2D vs 3D Models;ACS Biomaterials Science & Engineering;2023-02-02